Shareholders for Walgreens Boots Alliance overwhelmingly voted to approve the company’s sale to Sycamore Partners, with 96% of shareholders at a special meeting voting to green-light the merger, ...

The transaction, expected to close in Q3 or Q4, will take the company private after nearly 100 years as a public company. The ...

Walgreens Boots Alliance (WBA) said on Friday that the struggling drug retailer’s shareholders approved its $10 billion ...

Chief Clinical Trials Officer Ramita Tandon said the clinical trials unit has "a tremendous amount of commitment" from Walgreens' leadership.

Walgreens Boots Alliance (NASDAQ:WBA) reported stronger-than-expected earnings and revenue for its fiscal third quarter, as cost-cutting measures helped offset weakness in front-of-store sales. The ...

CVS, Walgreens & Walmart’s healthcare strategy faces headwinds: 10 notes from 2024 Walmart, CVS and Walgreens faced major headwinds in 2024 as their efforts to push into primary care faltered.

In this video interview, Ramita Tandon, chief biopharma officer at Walgreens, reflects on the company’s three-year evolution as a clinical trials partner, highlighting its pharmacy-led model and ...

US pharmacy Walgreens Boots Alliance (WBA) shareholders have given approval to the company's acquisition by Sycamore Partners Management affiliated entities. The preliminary results revealed that 96% ...

Walgreens Boots Alliance is being taken private in a deal valued up to $23.7 billion, following a largely disastrous run on the public markets where its market cap has lost billions and more than ...

Walgreens is selling its stake in VillageMD as CEO Tim Wentworth moves ahead with his turnaround strategy.

Walgreens is in the middle of a massive turnaround. The pharmacy chain plans to close up to 1,200 stores and announced ...